Search

Your search keyword '"Moeller F"' showing total 747 results
Start Over Author "Moeller F" Language english
747 results on '"Moeller F"'

13. Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.

Author

White, Augustus M., Eglovitch, Michelle, Parlier-Ahmad, Anna Beth, Dzierzewski, Joseph M., James, Morgan, Bjork, James M., Moeller, F. Gerard, and Martin, Caitlin E.

Subjects
INTEROCEPTION, OPIOID abuse, INSOMNIA, SLEEP interruptions, BUPRENORPHINE, ADULTS, MORBID obesity
Abstract

Objectives: Insomnia symptoms are negatively related to opioid use disorder (OUD) treatment outcomes, possibly reflecting the influence of sleep on neurofunctional domains implicated in addiction. Moreover, the intersection between OUD recovery and sleep represents an area well-suited for the development of novel, personalized treatment strategies. This study assessed the prevalence of clinically significant insomnia symptoms and characterized its neurofunctional correlates among a clinical sample of adults with OUD receiving buprenorphine. Methods: Adults (N = 129) receiving buprenorphine for OUD from an outpatient clinic participated in a cross-sectional survey. Participants completed an abbreviated version of NIDA's Phenotyping Assessment Battery, which assessed 6 neurofunctional domains: sleep, negative emotionality, metacognition, interoception, cognition, and reward. Bivariate descriptive statistics compared those with evidence of clinically significant insomnia symptoms (Insomnia Severity Index [ISI] score of ≥11) to those with minimal evidence of clinically significant insomnia symptoms (ISI score of ≤10) across each of the neurofunctional domains. Results: Roughly 60% of participants reported clinically significant insomnia symptoms (ISI score of ≥11). Experiencing clinically significant insomnia symptoms was associated with reporting greater levels of depression, anxiety, post-traumatic stress, stress intolerance, unhelpful metacognition, and interoceptive awareness (ps<0.05). Participants with evidence of clinically significant insomnia were more likely to report that poor sleep was interfering with their OUD treatment and that improved sleep would assist with their treatment (ps<0.05). Conclusions: Insomnia was prevalent among adults receiving buprenorphine for OUD. Insomnia was associated with neurofunctional performance, which may impact OUD treatment trajectories. Our findings indicate potential targets in the development of personalized treatment plans for patients with co-morbid insomnia and OUD. To inform the development of novel treatment strategies, more research is needed to understand the potential mechanistic links between sleep disturbances and substance use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda

Author

Kiluk, Brian D., Carroll, Kathleen M., Duhig, Amy, Falk, Daniel E., Kampman, Kyle, Lai, Shengan, Litten, Raye Z., McCann, David J., Montoya, Ivan D., Preston, Kenzie L., Skolnick, Phil, Weisner, Constance, Woody, George, Chandler, Redonna, Detke, Michael J., Dunn, Kelly, Dworkin, Robert H., Fertig, Joanne, Gewandter, Jennifer, Moeller, F. Gerard, Ramey, Tatiana, Ryan, Megan, Silverman, Kenneth, and Strain, Eric C.

Published
2016
Full Text
View/download PDF

36. Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug-seeking, but not self-administration, in male rats.

Author

Merritt, Christina R., Garcia, Erik J., Brehm, Victoria D., Fox, Robert G., Moeller, F. Gerard, Anastasio, Noelle C., and Cunningham, Kathryn A.

Subjects
GHRELIN receptors, APPETITE stimulants, COCAINE, OXYCODONE, DRUG overdose, SPRAGUE Dawley rats, MEDICATION therapy management
Abstract

The drug overdose crisis has spawned serious health consequences, including the increased incidence of substance use disorders (SUDs), conditions manifested by escalating medical and psychological impairments. While medication management is a key adjunct in SUD treatment, this crisis has crystallized the need to develop additional therapeutics to facilitate extended recovery from SUDs. The “hunger hormone” ghrelin acts by binding to the growth hormone secretagogue receptor 1α (GHS1αR) to control homeostatic and hedonic aspects of food intake and has been implicated in the mechanisms underlying SUDs. Preclinical studies indicate that GHS1αR antagonists and inverse agonists suppress reward-related signaling associated with cocaine and opioids. In the present study, we found that the GHS1αR antagonist JMV2959 was efficacious to suppress both cue-reinforced cocaine and oxycodone drug-seeking, but not cocaine or oxycodone self-administration in male Sprague-Dawley rats. These data suggest a role of the ghrelin-GHS1αR axis in mediating overlapping reward-related aspects of cocaine and oxycodone and premises the possibility that a GHS1αR antagonist may be a valuable therapeutic strategy for relapse vulnerability in SUDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder

Author

De La Garza, Richard, II, Bubar, Marcy J., Carbone, Crystal L., Moeller, F. Gerard, Newton, Thomas F., Anastasio, Noelle C., Harper, Tod A., Ware, David L., Fuller, Michael A., Holstein, Gaylyn J., Jayroe, Jason B., Bandak, Stephen I., Reiman, Kirsten Z., Neale, Ann C., Pickford, Lesley B., and Cunningham, Kathryn A.

Published
2015
Full Text
View/download PDF

50. Outcomes of Emergency Department Patients With Opioid Use Disorder Utilizing a Virtual Addiction Bridge Clinic: A Case Series.

Author

Wills, Brandon K., Ringwood, Katy J., Davis, Theresa T., Provost, Rosellen, Bachireddy, Chethan, Wang, Jennifer, Keyser-Marcus, Lori, and Moeller, F. Gerard

Abstract

Objectives: Within the last decade, there has been a dramatic increase in the rate of emergency department (ED) visits and death from opioid overdose. Those who present to the ED are at high risk for subsequent morbidity and mortality. Despite effective treatment, many patients do not get rapidly connected to outpatient care. The aim of this investigation was to describe outpatient treatment engagement after ED discharge among patients with opioid use disorder (OUD) enrolled in a virtual Addiction Bridge Clinic (ABC). Methods: This was a retrospective case series describing an ED-initiated referral for rapid telehealth follow-up among patients with OUD. The primary outcome was addiction treatment engagement among those who completed the initial virtual ABC visit (engaged in ABC) vs. those who did not complete anABCvisit (Not engaged inABC)at 1week, 1month, and 3 and 6 months timepoint intervals after the initial ED presentation. Results: Of the N = 201 patients referred to the ABC between March and December 2021, a majority were Black (71%) and male (77%). Of the 201 referrals, 85 (42%) completed an initial ABC telehealth visit. Subsequent treatment engagement was 26% at 1 week, 26% at 1 month, 22% at 3 months, and 18% at 6 months after the index ED visit. Conclusions: A telehealth-enabled virtual addiction bridge clinic is one potential approach to reduce barriers to rapid treatment access. Strategies are needed to improve subsequent addiction treatment engagement after a virtual addiction bridge clinic visit. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results